Patents Assigned to Syntro Corporation
-
Patent number: 5804372Abstract: The present invention provides recombinant infectious bovine rhinotracheitis (IBR) viruses useful in vaccines to protect bovines from infectious bovine rhinotracheitis and other bovine diseases. The present invention further provides methods for distinguishing an animal vaccinated with the vaccine of the present invention from an animal infected with a naturally-occurring IBR virus. The present invention also provides isolated DNA encoding the gpE glycoprotein of IBR virus and isolated DNA encoding the gpG glycoprotein of IBR virus.Type: GrantFiled: July 1, 1996Date of Patent: September 8, 1998Assignee: Syntro CorporationInventors: Mark D. Cochran, Richard D. Macdonald
-
Patent number: 5783195Abstract: The present invention provides a recombinant infectious bovine rhinotracheitis virus designated S-IBR-052 (ATCC Accession No. VR 2443). A vaccine is provided which comprises an effective immunizing amount of S-IBR-052 and a suitable carrier. A method of immunizing an animal against disease caused by infectious bovine rhinotracheitis virus is also provided which comprises administering to the animal an effective immunizing dose of the vaccine. The present invention also provides a method of distinguishing an animal vaccinated with the vaccine of the present invention from an animal infected with a naturally-occurring infectious bovine rhinotracheitis virus.Type: GrantFiled: February 4, 1994Date of Patent: July 21, 1998Assignee: Syntro CorporationInventors: Mark D. Cochran, Richard D. Macdonald
-
Patent number: 5763269Abstract: The present invention provides a hybrid, nonprimate herpesvirus comprising DNA which includes a sequence essential for viral replication of the hybrid, nonprimate herpesvirus, at least a portion of which is present in a sequence essential for replication of a naturally-occurring nonprimate herpesvirus and at least one foreign DNA sequence.Also provided is an attenuated, nonprimate herpesvirus comprising DNA which includes a sequence essential for viral replication of the attenuated, nonprimate herpesvirus, at least a portion of which is present in a sequence essential for replication of a naturally-occurring nonprimate herpesvirus, from which at least a portion of a repeat sequence has been deleted.Also provided are vaccines comprising the viruses of the invention and methods of immunizing animals against various disease.Type: GrantFiled: February 1, 1995Date of Patent: June 9, 1998Assignee: Syntro CorporationInventors: Mark D. Cochran, Meng-Fu Shih, William P. MacConnell, Richard D. MacDonald
-
Patent number: 5741696Abstract: The present invention relates to a non-naturally occurring, recombinant equine herpesvirus. The invention also relates to a recombinant equine herpesvirus capable of replication which comprises viral DNA from a species of equine herpesvirus and foreign DNA, the foreign DNA being inserted into the equine herpesviral DNA at a site which is not essential for replication of the equine herpesvirus. The invention also relates to DNA encoding the US2 protein of an equine herpesvirus. The invention relates to homology vectors for producing recombinant equine herpesviruses which produce recombinant equine herpesviruses by inserting foreign DNA into equine herpesviral DNA. The invention further relates to a method of producing a fetal-safe, live recombinant equine herpesvirus.Type: GrantFiled: February 17, 1994Date of Patent: April 21, 1998Assignee: Syntro CorporationInventors: Mark D. Cochran, Christina H. Chiang
-
Patent number: 5736319Abstract: The present invention provides an attenuated, genetically-engineered pseudorabies virus designated S-PRV-155 (ATCC Accession No. VR 2311). A vaccine is provided which comprises an effective immunizing amount of S-PRV-155 and a suitable carrier. A method of immunizing an animal against disease caused by pseudorabies virus is also provided which comprises administering to the animal an effective immunizing dose of the vaccine. The present invention also provides a method for distinguishing an animal vaccinated with the vaccine of the present invention from an animal infected with a naturally-occurring, wild-type pseudorabies virus.Type: GrantFiled: June 1, 1995Date of Patent: April 7, 1998Assignee: Syntro CorporationInventor: Mark D. Cochran
-
Patent number: 5731188Abstract: The present invention relates to a non-naturally occurring, recombinant equine herpesvirus. The invention also relates to a recombinant equine herpesvirus capable of replication which comprises viral DNA from a species of equine herpesvirus and foreign DNA, the foreign DNA being inserted into the equine herpesviral DNA at a site which is not essential for replication of the equine herpesvirus. The invention also relates to DNA encoding the US2 protein of an equine herpesvirus. The invention relates to homology vectors for producing recombinant equine herpesviruses which produce recombinant equine herpesviruses by inserting foreign DNA into equine herpesviral DNA. The invention further relates to a method of producing a fetal-safe, live recombinant equine herpesvirus.Type: GrantFiled: October 14, 1994Date of Patent: March 24, 1998Assignee: Syntro CorporationInventors: Mark D. Cochran, Christina H. Chiang
-
Patent number: 5599544Abstract: The present invention provides recombinant infectious bovine rhinotracheitis (IBR) viruses useful in vaccines to protect bovines from infectious bovine rhinotracheitis and other bovine diseases. The present invention further provides methods for distinguishing an animal vaccinated with the vaccine of the present invention from an animal infected with a naturally-occurring IBR virus. The present invention also provides isolated DNA encoding the gpE glycoprotein of IBR virus and isolated DNA encoding the gpG glycoprotein of IBR virus.Type: GrantFiled: June 7, 1995Date of Patent: February 4, 1997Assignees: PruTech Research and Development Partnership, Syntro CorporationInventors: Mark D. Cochran, Richard D. Macdonald
-
Patent number: 5593873Abstract: The present invention provides recombinant infectious bovine rhinotracheitis (IBR) viruses useful in vaccines to protect bovines from infectious bovine rhinotracheitis and other bovine diseases. The present invention further provides methods for distinguishing an animal vaccinated with the vaccine of the present invention from an animal infected with a naturally-occurring IBR virus. The present invention also provides isolated DNA encoding the gpE glycoprotein of IBR virus and isolated DNA encoding the gpG glycoprotein of IBR virus.Type: GrantFiled: May 23, 1994Date of Patent: January 14, 1997Assignees: Syntro Corporation, PruTech Research and Development PartnershipInventors: Mark D. Cochran, Richard D. Macdonald
-
Patent number: 5561063Abstract: The present invention provides a virus comprising a DNA sequence essential for replication of a human cytomegalovirus and at least one foreign DNA sequence adapted for expression in a host. The foreign DNA sequence may encode a human immunodeficiency virus anti-sense mRNA sequence or an antigenic polypeptide, e.g., a malarial surface antigen.Also provided are therapeutic compositions and vaccines which comprise the novel viruses of the present invention.Type: GrantFiled: December 9, 1993Date of Patent: October 1, 1996Assignee: Syntro CorporationInventors: Lisa J. Hock, Mark D. Cochran, Richard D. Macdonald
-
Patent number: 5451499Abstract: The present invention provides an attenuated, genetically-engineered pseudorabies virus designated S-PRY-155 (ATCC Accession No. VR 2311). A vaccine is provided which comprises an effective immunizing amount of S-PRY-155 and a suitable carrier. A method of immunizing an animal against disease caused by pseudorabies virus is also provided which comprises administering to the animal an effective immunizing dose of the vaccine. The present invention also provides a method for distinguishing an animal vaccinated with the vaccine of the present invention from an animal infected with a naturally-occurring, wild-type pseudorabies virus.Type: GrantFiled: April 30, 1993Date of Patent: September 19, 1995Assignee: Syntro CorporationInventor: Mark D. Cochran
-
Patent number: 5382425Abstract: The present invention relates to a recombinant swinepox virus capable of replication comprising foreign DNA inserted into a site in the swinepox viral DNA which is not essential for replication of the swinepox virus. The invention further relates to homology vectors which produce recombinant swinepox viruses by inserting foreign DNA into swinepox viral DNA.Type: GrantFiled: January 13, 1992Date of Patent: January 17, 1995Assignee: Syntro CorporationInventors: Mark D. Cochran, David E. Junker
-
Patent number: 5273876Abstract: The present invention provides a virus comprising a DNA sequence essential for replication of a human cytomegalovirus and at least one foreign DNA sequence adapted for expression in a host. The foreign DNA sequence may encode a human immunodeficiency virus anti-sense mRNA sequence or an antigenic polypeptide, e.g., a malarial surface antigen.Also provided are therapeutic compositions and vaccines which comprise the novel viruses of the present invention.Type: GrantFiled: October 16, 1990Date of Patent: December 28, 1993Assignee: Syntro CorporationInventors: Lisa J. Hock, Mark D. Cochran, Richard D. Macdonald
-
Patent number: 5240703Abstract: The present invention provides an attenuated, genetically-engineered pseudorabies virus designated S-PRV-155 (ATCC Accession No. VR 2311). A vaccine is provided which comprises an effective immunizing amount of S-PRV-155 and a suitable carrier. A method of immunizing an animal against disease caused by pseudorabies virus is also provided which comprises administering to the animal an effective immunizing dose of the vaccine. The present invention also provides a method for distinguishing an animal vaccinated with the vaccine of the present invention from an animal infected with a naturally-occurring, wild-type pseudorabies virus.Type: GrantFiled: March 1, 1991Date of Patent: August 31, 1993Assignee: Syntro CorporationInventor: Mark D. Cochran
-
Patent number: 5010001Abstract: Enhanced production of B. thuringiensis delta-endotoxin is achieved by employing the naturally occurring gene where an abbreviated 3'- and 5'-non-coding flanking region is employed. Particularly, the 3'-flanking does not extend past the downstream HincII cleavage site and the 5'-flanking region does not extend past the upstream HincII cleavage site. By having abbreviated flanking regions, enhanced production of the delta-endotoxin in E. coli is obtained.Type: GrantFiled: March 28, 1985Date of Patent: April 23, 1991Assignee: Syntro CorporationInventor: Thomas J. Pollock
-
Patent number: 4787963Abstract: Method and means for accelerating the rate of hybridization of nucleic acid probes with complemental target sequences in probe assays of the filter binding or sandwich filter binding formats. The nucleic acid probes are electrophoretically concentrated at membrane means including at least a dialysis type membrane and to which the target sequences are bound. The rate of hybridization can be further enhanced by means for moving concentrated unannealed probe molecules successively in various directions along the surface of the membrane means to which the target sequences are bound. The invention further includes method and means for electrophoretically removing from the membrane means unannealed probe molecules which became adsorbed to the membrane means during hybridization.Type: GrantFiled: May 4, 1987Date of Patent: November 29, 1988Assignee: Syntro CorporationInventor: William P. MacConnell
-
Patent number: 4652628Abstract: DNA sequences are provided coding for Bacillus thuringiensis var. israelensis (BTI) endotoxin, employing bacterial hosts which produce a protein having insecticidal activity for dipteran insects.The bacteriophage lambda strain SYN A4-1 was deposited at the A.T.C.C. on Feb. 22, 1984 and given Accession No. 40098.Type: GrantFiled: January 22, 1985Date of Patent: March 24, 1987Assignee: Syntro CorporationInventors: Alan M. Walfield, Thomas J. Pollock